The PREVCOG study: longitudinal and multimodal biomarker analyses for secondary prevention of Alzheimer's disease and cognitive decline in French memory clinics

Abstract

Background: While research on Alzheimer's disease has recently made significant progress with the approval of two disease‐modifying treatments and the development of blood‐based biomarkers predicted to revolutionize AD diagnosis, questions remain—particularly regarding the value of amyloidopathy in predicting cognitive decline on its own.